Asset / Drug

Enicepatide

Drug and asset intelligence for Enicepatide with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Roche →

Mechanism of action

GIP Receptor Agonist and Amylin Analog

Recent signals(2)

CompetitiveJune 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

CompetitiveJune 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Roche — Enicepatide

Roche's promising Phase II data on enicepatide and petrelintide positions the company as a formidable player in the obesity treatment market. This advancement could significantly impact market dynamics, compelling competitors to reassess their strategies.

June 16, 2026 · N/A

Topline Data

Roche — Enicepatide

Roche's promising Phase II data for enicepatide and petrelintide positions the company favorably in the competitive obesity treatment landscape. This advancement could redefine market dynamics and influence strategic resource allocation and partnerships in the obesity therapeutic area.

June 16, 2026 · N/A

Indications

Obesity →

Therapeutic areas

GIP Receptor Agonist and Amylin Analog →

GLP-1 →

Obesity →

Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.